Astrazeneca
Clinical trials sponsored by Astrazeneca, explained in plain language.
-
New daily pill could help millions shed pounds
Disease control Not yet recruitingThis phase 3 trial is testing a new daily pill called elecoglipron for weight loss in 4500 adults who are obese or overweight, with or without type 2 diabetes. Participants will take the pill or a placebo for 72 weeks, alongside diet and exercise. The main goal is to see how much…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New diabetes drug aims to help those with kidney disease
Disease control Not yet recruitingThis study tests a new daily pill called elecoglipron in adults with type 2 diabetes and reduced kidney function. Participants also take dapagliflozin, a standard diabetes medicine. The goal is to see if elecoglipron improves blood sugar control, body weight, and blood pressure c…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New diabetes pill elecoglipron faces final test in 600-Patient trial
Disease control Not yet recruitingThis phase 3 study tests whether a new oral drug called elecoglipron can help adults with type 2 diabetes better manage their blood sugar when added to their current insulin and other diabetes medications. About 600 participants will receive either elecoglipron or a placebo daily…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New pill combo aims to tame type 2 diabetes
Disease control Not yet recruitingThis study tests an experimental drug called elecoglipron, taken alone or together with the existing medication dapagliflozin, in adults with type 2 diabetes whose blood sugar is not well controlled. About 800 participants will receive either the new drug, a placebo, or a combina…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Diabetes duo: could a Two-Pill combo tame blood sugar better than one?
Disease control Not yet recruitingThis phase 3 study tests whether taking two diabetes medications together—elecoglipron and dapagliflozin—works better than either drug alone for controlling blood sugar in adults with type 2 diabetes. The trial enrolls about 2,000 people whose diabetes is not well managed by life…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New daily pill aims to rival semaglutide for diabetes and weight loss
Disease control Not yet recruitingThis phase 3 study tests a new oral drug, elecoglipron, against the approved pill semaglutide in adults with type 2 diabetes who also have increased heart risk. The goal is to see which works better for lowering blood sugar and body weight over about a year. Participants take one…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New pill combo aims to delay chemo in advanced breast cancer
Disease control Not yet recruitingThis phase 3 trial is testing two oral drugs, camizestrant and ribociclib, as a first treatment for people with ER-positive, HER2-negative advanced breast cancer. The goal is to see if the combination can delay the need for next cancer therapy. About 150 participants will take th…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New study tests tezepelumab for chronic sinusitis sufferers
Disease control Not yet recruitingThis study follows 200 adults with severe chronic sinusitis and nasal polyps who are starting tezepelumab as part of their routine care. Researchers will track changes in symptoms and quality of life over up to two years using patient questionnaires. The goal is to see how well t…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New lupus drug tested in kids for first time
Disease control Not yet recruitingThis study tests anifrolumab, a drug already used in adults with lupus, in children aged 5 to 17. The goal is to see how the drug moves through the body and if it is safe. Twenty-four children with moderate to severe lupus will receive the drug as a shot under the skin, while con…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New study monitors Real-World safety of asthma drug tezepelumab in korea
Disease control Not yet recruitingThis study observes 210 patients in South Korea who are prescribed Tezepelumab for severe asthma or chronic sinusitis with nasal polyps. Researchers will track side effects and how well the drug controls symptoms in everyday use. The goal is to confirm the drug's safety and effec…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New combo pill aims to supercharge cholesterol lowering
Disease control Not yet recruitingThis Phase 3 trial tests whether a new combination pill containing laroprovstat and rosuvastatin lowers LDL cholesterol better than rosuvastatin alone. About 200 adults with high cholesterol and a history of heart disease or high risk will take either the combo or a placebo plus …
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New cholesterol combo pill aims to slash bad cholesterol without prior meds
Disease control Not yet recruitingThis study tests a new pill that combines two drugs (laroprovstat and rosuvastatin) to lower LDL or 'bad' cholesterol. About 600 adults with high cholesterol who have never taken cholesterol-lowering medication will receive either the combination, one of the drugs alone, or a pla…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug combo aims to slow kidney failure in High-Risk patients
Disease control Not yet recruitingThis phase 3 trial tests whether a combination of two drugs (balcinrenone and dapagliflozin) works better than dapagliflozin alone for people with advanced chronic kidney disease (stages 3b and 4). About 2,800 participants will take the combination or a placebo daily, alongside s…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
COPD drug breztri under Real-World watch in korea
Disease control Not yet recruitingThis study will follow 600 adults in Korea who have been prescribed Breztri for COPD, a long-term lung disease. Researchers want to see how safe the drug is in everyday use and whether it works as expected. Participants will take Breztri as their doctor prescribes, and the study …
Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Roll-Over study offers continued benralizumab access for patients who benefit
Disease control Not yet recruitingThis study gives ongoing access to benralizumab (Fasenra) for people with asthma, eosinophilic granulomatosis with polyangiitis (EGPA), or hypereosinophilic syndrome (HES) who completed a prior benralizumab trial and still benefit from the drug. About 230 participants will receiv…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Real-World study tracks Ravulizumab's impact on rare kidney disease
Disease control Not yet recruitingThis study will follow about 80 Polish patients with atypical hemolytic uremic syndrome (aHUS) who are receiving ravulizumab (Ultomiris) as part of routine care. Researchers will collect data from medical records and follow patients over time to see how well the drug controls the…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New combo aims to tackle returning blood cancer
Disease control Not yet recruitingThis phase 2 trial tests a combination of two drugs, acalabrutinib and venetoclax, in 80 people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose cancer has returned after initial treatment. Participants must have responded well to their first ther…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Mouthwash may stop cancer Drug's painful side effect
Symptom relief Not yet recruitingThis study tests if a steroid mouthwash can prevent or reduce mouth sores caused by the cancer drug datopotamab deruxtecan (Dato-DXd). About 100 adults with advanced breast or lung cancer will use the mouthwash and be monitored for 12 weeks. The goal is to see if this simple step…
Phase: PHASE4 • Sponsor: AstraZeneca • Aim: Symptom relief
Last updated Jun 27, 2026 08:13 UTC
-
AI could help detect lung cancer earlier in High-Risk smokers
Knowledge-focused Not yet recruitingThis study will enroll 1,500 current or former smokers aged 50-80 to see if an artificial intelligence (AI) model can help doctors better detect lung nodules and predict cancer spread. Participants will undergo CT scans, and the AI's results will be compared to standard radiologi…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Real-World study eyes drug combo for tough prostate cancer
Knowledge-focused Not yet recruitingThis study observes how well a combination of two drugs, olaparib and abiraterone, works as a first treatment for men with metastatic castration-resistant prostate cancer who have already tried other hormone therapies. Researchers will track how long patients stay on the treatmen…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Brazil tests lung cancer screening in smokers
Knowledge-focused Not yet recruitingThis study will screen 477 current or former smokers in Brazil for lung cancer using CT scans. It aims to see how often the scans give false alarms (false positives) in a region where lung infections are common. The goal is to improve screening accuracy and reduce unnecessary fol…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Greek sinusitis study aims to personalize treatment by analyzing inflammation
Knowledge-focused Not yet recruitingThis study will collect and analyze nasal tissue from 230 Greek patients with chronic sinusitis (with or without nasal polyps) to identify different inflammation patterns, called endotypes. By understanding these patterns, researchers hope to better match patients with the most e…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
New study tracks safety of eplontersen in patients with liver transplants
Knowledge-focused Not yet recruitingThis observational study monitors the long-term safety of eplontersen, a treatment for transthyretin amyloidosis, in patients who have had a liver transplant or have severe liver impairment. Researchers will track side effects, lab changes, and serious health events in about 320 …
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Massive study aims to standardize lung cancer testing across labs
Knowledge-focused Not yet recruitingThis study involves 3,400 people with advanced non-small cell lung cancer to see if a new test for a protein called TROP2 works consistently across different laboratories. The goal is to ensure that doctors can reliably use this test to guide treatment decisions. Participants pro…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Tiny study could unlock secrets of genetic heart failure
Knowledge-focused Not yet recruitingThis study follows 10 Chinese adults who have a specific gene mutation (BAG3) linked to dilated cardiomyopathy, a condition where the heart becomes enlarged and weak. Researchers will track changes in heart function, symptoms, and biomarkers over time to better understand how the…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New drug AZD4916 put to the test in healthy people first
Knowledge-focused Not yet recruitingThis early-stage study tests whether the experimental drug AZD4916 is safe and how it moves through the body in 160 healthy adults, including Japanese and Chinese volunteers. Participants receive either the drug or a placebo, and researchers monitor for side effects. This study d…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Massive review of 4,000 liver cancer patients aims to uncover regional trends
Knowledge-focused Not yet recruitingThis study will collect and analyze medical records from about 4,000 adults diagnosed with liver cancer (hepatocellular carcinoma) in Middle Eastern and North African countries between 2015 and 2023. Researchers want to understand what causes the cancer, how it is treated, and wh…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Tracing a cancer Drug's journey through the body
Knowledge-focused Not yet recruitingThis study tracks how the experimental drug AZD1390 moves through and leaves the body after a single dose. It involves about 8 adults with advanced solid tumors who are not currently on active cancer treatment. By using a tiny radioactive label, researchers can measure the drug i…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Can more screening catch lung cancer sooner? big study aims to find out
Knowledge-focused Not yet recruitingThis study looks at medical records of 3,000 adults with lung cancer to see if the stage at diagnosis is shifting to earlier, more curable stages. Researchers will track how often cancer is found through screening programs, chest X-rays, or heart scans. No new treatments or tests…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC
-
New drug AZD7760 tested in healthy volunteers for safety
Knowledge-focused Not yet recruitingThis early-stage study tests the safety of a new drug called AZD7760 in 18 healthy Japanese adults. Participants receive a single intravenous dose and are monitored for side effects and how the drug moves through the body. The study does not aim to treat any disease; it only gath…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
New study tracks Real-World success of breast cancer drug in GCC
Knowledge-focused Not yet recruitingThis study will follow about 109 women in Gulf Cooperation Council (GCC) countries who have a certain type of advanced breast cancer (HR-positive, HER2-low or ultra-low) and are taking the drug trastuzumab deruxtecan after hormone therapy stopped working. Researchers want to see …
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC
-
Massive Real-World study to see if targeted pills boost survival after lung cancer surgery
Knowledge-focused Not yet recruitingThis observational study will follow about 2,000 patients in China who have early-stage lung cancer with a specific gene mutation (EGFR) and have received targeted therapy pills (EGFR-TKIs) after surgery. Researchers will track how long patients live and how long they stay cancer…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC
-
Kazakhstan cancer study to reveal Real-World treatment patterns
Knowledge-focused Not yet recruitingThis study will review medical records of about 240 adults in Kazakhstan with HER2-positive metastatic breast cancer to see how they were treated and how well they did. Researchers will look at treatments given in routine care (except one specific drug) and track outcomes like ho…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
Why do lung cancer patients quit a key drug? new study seeks answers
Knowledge-focused Not yet recruitingThis study interviews about 85 patients with early-stage non-small cell lung cancer and 15 doctors to find out what makes it hard or easy to keep taking the drug osimertinib after surgery. The goal is to identify barriers like side effects, cost, or communication issues, and faci…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
Brazilian study maps prostate cancer genes to improve treatment
Knowledge-focused Not yet recruitingThis study aims to learn about genetic changes in metastatic prostate cancer and how they affect patient outcomes. Researchers will collect and analyze tissue and blood samples from 100 adults in Brazil who are receiving standard palliative therapy. The goal is to better understa…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
Lupus drug saphnelo under Real-World watch in women
Knowledge-focused Not yet recruitingThis study will look at how the lupus medication Saphnelo (anifrolumab) is being used in women aged 15 to 50 who could become pregnant. Researchers will track how many women use the drug each year and describe their health characteristics. The goal is to gather real-world informa…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:08 UTC